bepecin bpc-157 clinical trial Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing Multifunctionality and Possible Medical Application

Human growth hormones dictate things like our metabolism and body composition

It also has high affinity for H 1 histaminergic receptors equal to that at 5-HT 2A receptors

17 July 2026 BPC-157 remains unapproved

Maurer M, Berger W, Gimnez-Arnau A, Hayama K, Jain V, Reich A, et al

Methods Patient selection The inclusion criteria for the patients were as follows: patients 1) with histologically or cytologically proven non-Sq NSCLC and MPM, 2) planning to use pemetrexed-containing chemotherapy, 3) nave or previously treated with chemotherapy, 4) with ECOG-PS of 02, 5) age 20 years, 6) with adequate organ function measured as leukocyte count 3,000 /L, hemoglobin concentration 10.0 g/dL, platelet count 100,000 /L, total bilirubin level 2.0 mg/dL, transaminase levels 100 IU/L, serum creatinine level 1.5 mg/dL, SpO 2 (percutaneous oxygen saturation) 90% in ambient air, 7) expected to survive at least 12 weeks from the start of treatment, and 8) who provided written informed consent

These products may be applied at different times of the day